DK2934582T3 - Anti-her2-antistofformulering - Google Patents
Anti-her2-antistofformulering Download PDFInfo
- Publication number
- DK2934582T3 DK2934582T3 DK13808043.7T DK13808043T DK2934582T3 DK 2934582 T3 DK2934582 T3 DK 2934582T3 DK 13808043 T DK13808043 T DK 13808043T DK 2934582 T3 DK2934582 T3 DK 2934582T3
- Authority
- DK
- Denmark
- Prior art keywords
- her2 antibody
- antibody formulation
- formulation
- her2
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745293P | 2012-12-21 | 2012-12-21 | |
PCT/EP2013/077166 WO2014096051A1 (en) | 2012-12-21 | 2013-12-18 | Anti her2 antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2934582T3 true DK2934582T3 (da) | 2020-02-24 |
Family
ID=49779926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13808043.7T DK2934582T3 (da) | 2012-12-21 | 2013-12-18 | Anti-her2-antistofformulering |
Country Status (16)
Country | Link |
---|---|
US (2) | US20150343058A1 (da) |
EP (1) | EP2934582B1 (da) |
JP (2) | JP6400595B2 (da) |
AU (1) | AU2013360812B2 (da) |
BR (1) | BR112015014853A2 (da) |
CA (1) | CA2895869C (da) |
DK (1) | DK2934582T3 (da) |
EA (1) | EA201391729A1 (da) |
ES (1) | ES2773103T3 (da) |
HK (1) | HK1215796A1 (da) |
IL (1) | IL239509A0 (da) |
MX (2) | MX367748B (da) |
PL (1) | PL2934582T3 (da) |
SG (1) | SG11201504897YA (da) |
WO (1) | WO2014096051A1 (da) |
ZA (1) | ZA201504564B (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
CN112566942A (zh) * | 2018-07-25 | 2021-03-26 | 第一三共株式会社 | 用于制造抗体-药物缀合物的有效方法 |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
AR119293A1 (es) | 2019-06-28 | 2021-12-09 | Genentech Inc | Composición y métodos para estabilizar formulaciones líquidas de proteínas |
US20220273796A1 (en) * | 2019-07-19 | 2022-09-01 | Ichnos Sciences SA | Lyophilized antibody formulation |
WO2021174113A1 (en) | 2020-02-28 | 2021-09-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind her2, and methods of use thereof |
CN114762727A (zh) * | 2021-01-15 | 2022-07-19 | 海正生物制药有限公司 | 一种稳定的帕妥珠单抗的药物组合物 |
WO2023140807A1 (en) * | 2022-01-19 | 2023-07-27 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of trastuzumab |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03504605A (ja) * | 1988-05-27 | 1991-10-09 | セントカー・インコーポレーテツド | 抗体産生物の凍結乾燥した配合物 |
SI2275119T1 (sl) * | 1995-07-27 | 2013-12-31 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
IL133220A0 (en) * | 1997-06-13 | 2001-03-19 | Genentech Inc | Stabilized antibody formulation |
WO2003062375A2 (en) * | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
CA2490423A1 (en) * | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DK2390267T3 (da) * | 2005-06-07 | 2013-08-26 | Esbatech A Novartis Co Llc | Stabile og opløselige antistoffer, der hæmmer TNF(alfa) |
MX2007015476A (es) * | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
-
2013
- 2013-12-18 SG SG11201504897YA patent/SG11201504897YA/en unknown
- 2013-12-18 US US14/654,096 patent/US20150343058A1/en not_active Abandoned
- 2013-12-18 CA CA2895869A patent/CA2895869C/en active Active
- 2013-12-18 PL PL13808043T patent/PL2934582T3/pl unknown
- 2013-12-18 ES ES13808043T patent/ES2773103T3/es active Active
- 2013-12-18 BR BR112015014853A patent/BR112015014853A2/pt not_active Application Discontinuation
- 2013-12-18 AU AU2013360812A patent/AU2013360812B2/en not_active Ceased
- 2013-12-18 MX MX2015008194A patent/MX367748B/es active IP Right Grant
- 2013-12-18 JP JP2015548495A patent/JP6400595B2/ja not_active Expired - Fee Related
- 2013-12-18 DK DK13808043.7T patent/DK2934582T3/da active
- 2013-12-18 WO PCT/EP2013/077166 patent/WO2014096051A1/en active Application Filing
- 2013-12-18 EP EP13808043.7A patent/EP2934582B1/en active Active
- 2013-12-19 EA EA201391729A patent/EA201391729A1/ru unknown
-
2015
- 2015-06-18 IL IL239509A patent/IL239509A0/en unknown
- 2015-06-22 MX MX2019010479A patent/MX2019010479A/es unknown
- 2015-06-24 ZA ZA2015/04564A patent/ZA201504564B/en unknown
-
2016
- 2016-04-01 HK HK16103770.2A patent/HK1215796A1/zh not_active IP Right Cessation
-
2018
- 2018-09-05 JP JP2018165536A patent/JP2018199720A/ja active Pending
-
2019
- 2019-07-08 US US16/504,411 patent/US20200061190A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2895869A1 (en) | 2014-06-26 |
WO2014096051A9 (en) | 2014-10-02 |
WO2014096051A1 (en) | 2014-06-26 |
MX367748B (es) | 2019-09-04 |
AU2013360812A1 (en) | 2015-07-09 |
HK1215796A1 (zh) | 2016-09-15 |
EP2934582B1 (en) | 2019-11-27 |
ES2773103T3 (es) | 2020-07-09 |
MX2015008194A (es) | 2016-02-05 |
PL2934582T3 (pl) | 2020-08-10 |
US20200061190A1 (en) | 2020-02-27 |
SG11201504897YA (en) | 2015-07-30 |
CA2895869C (en) | 2020-09-22 |
EP2934582A1 (en) | 2015-10-28 |
US20150343058A1 (en) | 2015-12-03 |
JP6400595B2 (ja) | 2018-10-03 |
ZA201504564B (en) | 2016-11-30 |
AU2013360812B2 (en) | 2018-11-08 |
JP2018199720A (ja) | 2018-12-20 |
EA201391729A1 (ru) | 2014-09-30 |
MX2019010479A (es) | 2019-10-15 |
JP2016508973A (ja) | 2016-03-24 |
BR112015014853A2 (pt) | 2017-08-22 |
IL239509A0 (en) | 2015-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR24C1019I1 (fr) | Anticorps anti-fcrn | |
DK2858671T3 (da) | Antistofformulering | |
DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
DK3117837T3 (da) | Antistofformuleringer | |
DK2934584T3 (da) | Anti-gdf15-antistoffer | |
DK3049441T3 (da) | Anti-PDL1-antistofformuleringer | |
CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
BR112014024769A2 (pt) | anticorpo humanizado tau | |
CO7020871A2 (es) | Anticuerpos anti-il-36r | |
CR20130677A (es) | FORMULACIÓN PARA ANTICUERPO ANTI-a4ß7 | |
DK2847231T3 (da) | Multispecifikke monoklonale antistoffer | |
DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
CR20140127A (es) | Anticuerpo anti-abtcr | |
BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
CO6801637A2 (es) | Formulaciones de anticuerpos | |
BR112014032798A2 (pt) | composição | |
DK2934582T3 (da) | Anti-her2-antistofformulering | |
BR112014000015A2 (pt) | formulação | |
DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
DK3068800T3 (da) | FcRn-specifikke antistoffer | |
DK2931748T3 (da) | Bmp-6-antistoffer | |
DK3431504T3 (da) | Antiphospholipase d4-antistof | |
CL2014003125A1 (es) | Anticuerpos de anti-transglutaminasa 2 | |
UA25626S (uk) | Печиво | |
DK2935330T3 (da) | Anti-notch3-antistoffer |